The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

(2016) Jing Ni et al.   NATURE MEDICINE

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

(2015) Carlotta Costa et al.   CANCER CELL

Emerging Strategies for Treating Brain Metastases from Breast Cancer

(2015) David P. Kodack et al.   CANCER CELL

Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance

(2015) Jodi M Saunus et al.   JOURNAL OF PATHOLOGY

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

(2015) Vasileios Askoxylakis et al.   JNCI-Journal of the National Cancer Institute

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines

(2015) Majid Momeny et al.   Oncotarget

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

(2015) Vasileios Askoxylakis et al.   JNCI-Journal of the National Cancer Institute

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases

(2014) Lin Mei et al.   NEURON

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

(2013) E. M. Olson et al.   ANNALS OF ONCOLOGY

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

(2013) A. P. Garner et al.   CANCER RESEARCH

Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications

(2013) Donna H. Murrell et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

(2013) K. Tamura et al.   JOURNAL OF NUCLEAR MEDICINE

HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer

(2013) S. Verma et al.   ONCOLOGIST

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

(2012) Dhara N. Amin et al.   BIOCHEMICAL JOURNAL

Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel

(2012) Alan Huang et al.   CANCER RESEARCH

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

(2012) Thomas Bachelot et al.   LANCET ONCOLOGY

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases

(2012) D. P. Kodack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth

(2012) Fred Harbinski et al.   Cancer Discovery

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

(2011) D. Koul et al.   CLINICAL CANCER RESEARCH

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Real-time imaging reveals the single steps of brain metastasis formation

(2009) Yvonne Kienast et al.   NATURE MEDICINE

Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases

(2009) Euiheon Chung et al.   PLoS One

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2008) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY